Fig. 2From: Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataPooled hazard ratios for the outcomes of hospitalization for heart failure, all-cause death, composite of hospitalization for heart failure or all-cause death, myocardial infarction, and stroke (Intent-to-treat analysis; unadjusted). ACD all-cause death, HF heart failure, oGLD other glucose-lowering drug, PY patient–years, SGLT-2i sodium–glucose cotransporter-2 inhibitorBack to article page